922 related articles for article (PubMed ID: 33902106)
1. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia.
Yankova E; Blackaby W; Albertella M; Rak J; De Braekeleer E; Tsagkogeorga G; Pilka ES; Aspris D; Leggate D; Hendrick AG; Webster NA; Andrews B; Fosbeary R; Guest P; Irigoyen N; Eleftheriou M; Gozdecka M; Dias JML; Bannister AJ; Vick B; Jeremias I; Vassiliou GS; Rausch O; Tzelepis K; Kouzarides T
Nature; 2021 May; 593(7860):597-601. PubMed ID: 33902106
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule inhibition of the METTL3/METTL14 complex suppresses neuroblastoma tumor growth and promotes differentiation.
Pomaville M; Chennakesavalu M; Wang P; Jiang Z; Sun HL; Ren P; Borchert R; Gupta V; Ye C; Ge R; Zhu Z; Brodnik M; Zhong Y; Moore K; Salwen H; George RE; Krajewska M; Chlenski A; Applebaum MA; He C; Cohn SL
Cell Rep; 2024 May; 43(5):114165. PubMed ID: 38691450
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a PROTAC degrader for METTL3-METTL14 complex.
Du W; Huang Y; Chen X; Deng Y; Sun Y; Yang H; Shi Q; Wu F; Liu G; Huang H; Ding J; Huang X; Xu S
Cell Chem Biol; 2024 Jan; 31(1):177-183.e17. PubMed ID: 38194973
[TBL] [Abstract][Full Text] [Related]
4. Promoter-bound METTL3 maintains myeloid leukaemia by m
Barbieri I; Tzelepis K; Pandolfini L; Shi J; Millán-Zambrano G; Robson SC; Aspris D; Migliori V; Bannister AJ; Han N; De Braekeleer E; Ponstingl H; Hendrick A; Vakoc CR; Vassiliou GS; Kouzarides T
Nature; 2017 Dec; 552(7683):126-131. PubMed ID: 29186125
[TBL] [Abstract][Full Text] [Related]
5. The N
Vu LP; Pickering BF; Cheng Y; Zaccara S; Nguyen D; Minuesa G; Chou T; Chow A; Saletore Y; MacKay M; Schulman J; Famulare C; Patel M; Klimek VM; Garrett-Bakelman FE; Melnick A; Carroll M; Mason CE; Jaffrey SR; Kharas MG
Nat Med; 2017 Nov; 23(11):1369-1376. PubMed ID: 28920958
[TBL] [Abstract][Full Text] [Related]
6. A Stapled Peptide Inhibitor Targeting the Binding Interface of N6-Adenosine-Methyltransferase Subunits METTL3 and METTL14 for Cancer Therapy.
Li Z; Feng Y; Han H; Jiang X; Chen W; Ma X; Mei Y; Yuan D; Zhang D; Shi J
Angew Chem Int Ed Engl; 2024 Jun; 63(24):e202402611. PubMed ID: 38607929
[TBL] [Abstract][Full Text] [Related]
7. METTL3 inhibition reduces N
Li S; Zou D; Chen W; Britz GW; Liu Z; Weng YL
Immunol Cell Biol; 2022 Oct; 100(9):718-730. PubMed ID: 36005900
[TBL] [Abstract][Full Text] [Related]
8. The m
Sang L; Wu X; Yan T; Naren D; Liu X; Zheng X; Zhang N; Wang H; Li Y; Gong Y
J Cancer; 2022; 13(3):1019-1030. PubMed ID: 35154467
[TBL] [Abstract][Full Text] [Related]
9. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
Rau RE; Rodriguez BA; Luo M; Jeong M; Rosen A; Rogers JH; Campbell CT; Daigle SR; Deng L; Song Y; Sweet S; Chevassut T; Andreeff M; Kornblau SM; Li W; Goodell MA
Blood; 2016 Aug; 128(7):971-81. PubMed ID: 27335278
[TBL] [Abstract][Full Text] [Related]
10. Roles of METTL3 in cancer: mechanisms and therapeutic targeting.
Zeng C; Huang W; Li Y; Weng H
J Hematol Oncol; 2020 Aug; 13(1):117. PubMed ID: 32854717
[TBL] [Abstract][Full Text] [Related]
11. Essential role of METTL3-mediated m
Visvanathan A; Patil V; Arora A; Hegde AS; Arivazhagan A; Santosh V; Somasundaram K
Oncogene; 2018 Jan; 37(4):522-533. PubMed ID: 28991227
[TBL] [Abstract][Full Text] [Related]
12. Roles and drug development of METTL3 (methyltransferase-like 3) in anti-tumor therapy.
Xu P; Ge R
Eur J Med Chem; 2022 Feb; 230():114118. PubMed ID: 35063732
[TBL] [Abstract][Full Text] [Related]
13. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
[TBL] [Abstract][Full Text] [Related]
14. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
[TBL] [Abstract][Full Text] [Related]
15. METTL3 mediates chemoresistance by enhancing AML homing and engraftment via ITGA4.
Li M; Ye J; Xia Y; Li M; Li G; Hu X; Su X; Wang D; Zhao X; Lu F; Li J; Ma D; Sun T; Ji C
Leukemia; 2022 Nov; 36(11):2586-2595. PubMed ID: 36266324
[TBL] [Abstract][Full Text] [Related]
16. m
Chen J; Zhang YC; Huang C; Shen H; Sun B; Cheng X; Zhang YJ; Yang YG; Shu Q; Yang Y; Li X
Genomics Proteomics Bioinformatics; 2019 Apr; 17(2):154-168. PubMed ID: 31154015
[TBL] [Abstract][Full Text] [Related]
17. Eltrombopag as an Allosteric Inhibitor of the METTL3-14 Complex Affecting the m
Lee JH; Choi N; Kim S; Jin MS; Shen H; Kim YC
Pharmaceuticals (Basel); 2022 Apr; 15(4):. PubMed ID: 35455436
[TBL] [Abstract][Full Text] [Related]
18. METTL3/METTL14 Transactivation and m
Feng Y; Dong H; Sun B; Hu Y; Yang Y; Jia Y; Jia L; Zhong X; Zhao R
Cell Mol Gastroenterol Hepatol; 2021; 12(3):839-856. PubMed ID: 33992834
[TBL] [Abstract][Full Text] [Related]
19. The Distinct Function and Localization of METTL3/METTL14 and METTL16 Enzymes in Cardiomyocytes.
Arcidiacono OA; Krejčí J; Bártová E
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33143367
[TBL] [Abstract][Full Text] [Related]
20. Tumor-suppressive MEG3 induces microRNA-493-5p expression to reduce arabinocytosine chemoresistance of acute myeloid leukemia cells by downregulating the METTL3/MYC axis.
Wang A; Chen Y; Shi L; Li M; Li L; Wang S; Wang C
J Transl Med; 2022 Jun; 20(1):288. PubMed ID: 35761379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
